Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 746

1.

In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy.

Ferone D, Pivonello R, Lastoria S, Faggiano A, Del Basso de Caro ML, Cappabianca P, Lombardi G, Colao A.

Clin Endocrinol (Oxf). 2001 Apr;54(4):469-77.

PMID:
11318782
2.

Optimizing medical therapy of acromegaly: beneficial effects of cabergoline in patients uncontrolled with long-acting release octreotide.

Jallad RS, Bronstein MD.

Neuroendocrinology. 2009;90(1):82-92. doi: 10.1159/000218323. Epub 2009 May 8.

PMID:
19439914
3.
4.

The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.

Di Sarno A, Landi ML, Marzullo P, Di Somma C, Pivonello R, Cerbone G, Lombardi G, Colao A.

Clin Endocrinol (Oxf). 2000 Jul;53(1):53-60.

PMID:
10931080
5.

Correlation of scintigraphic results using 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas.

Ferone D, Lastoria S, Colao A, Varrella P, Cerbone G, Acampa W, Merola B, Salvatore M, Lombardi G.

J Clin Endocrinol Metab. 1998 Jan;83(1):248-52.

PMID:
9435450
6.

In vivo imaging of pituitary tumours using a radiolabelled dopamine D2 receptor radioligand.

de Herder WW, Reijs AE, Kwekkeboom DJ, Hofland LJ, Nobels FR, Oei HY, Krenning EP, Lamberts SW.

Clin Endocrinol (Oxf). 1996 Dec;45(6):755-67.

PMID:
9039343
7.

Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas.

Saveanu A, Gunz G, Guillen S, Dufour H, Culler MD, Jaquet P.

Neuroendocrinology. 2006;83(3-4):258-63. Epub 2006 Oct 13.

PMID:
17047391
8.

Receptor imaging with 111In-pentreotide and 123I-methoxybenzamide, and inhibition tests with octreotide and bromocriptine of mixed growth hormone/prolactin-secreting pituitary tumors.

Panza N, Rambaldi PF, Battista C, Ambrosio G, Cascini GL, Schillirò F, Mansi L.

Biomed Pharmacother. 1999 Aug;53(7):319-22.

PMID:
10472432
9.

Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy.

Ferone D, de Herder WW, Pivonello R, Kros JM, van Koetsveld PM, de Jong T, Minuto F, Colao A, Lamberts SW, Hofland LJ.

J Clin Endocrinol Metab. 2008 Apr;93(4):1412-7. doi: 10.1210/jc.2007-1358. Epub 2008 Jan 22.

PMID:
18211974
10.

Acute effects of octreotide, cabergoline and a combination of both drugs on GH secretion in acromegalic patients.

Minniti G, Jaffrain-Rea ML, Baldelli R, Ferretti E, Caracciolo B, Bultrini A, Gulino A, Tamburrano G.

Clin Ter. 1997 Dec;148(12):601-7.

PMID:
9528195
11.

BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide.

Jaquet P, Gunz G, Saveanu A, Barlier A, Dufour H, Taylor J, Dong J, Kim S, Moreau JP, Culler MD.

J Endocrinol Invest. 2005;28(11 Suppl International):21-7.

PMID:
16625841
12.

Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients.

Marzullo P, Ferone D, Di Somma C, Pivonello R, Filippella M, Lombardi G, Colao A.

Pituitary. 1999;1(2):115-20.

PMID:
11081189
13.

[Novel pharmacologic therapies in acromegaly].

Góth M, Hubina E, Kovács L, Szabolcs I.

Orv Hetil. 2002 May 12;143(19 Suppl):1057-62. Review. Hungarian.

PMID:
12063860
14.
15.
16.

Short- and long-term efficacy of combined cabergoline and octreotide treatment in controlling igf-I levels in acromegaly.

Mattar P, Alves Martins MR, Abucham J.

Neuroendocrinology. 2010;92(2):120-7. doi: 10.1159/000317314. Epub 2010 Aug 25.

PMID:
20802256
17.

Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogues and dopastatins.

Gatto F, Barbieri F, Gatti M, Wurth R, Schulz S, Ravetti JL, Zona G, Culler MD, Saveanu A, Giusti M, Minuto F, Hofland LJ, Ferone D, Florio T.

Clin Endocrinol (Oxf). 2012 Mar;76(3):407-14. doi: 10.1111/j.1365-2265.2011.04200.x.

PMID:
21848909
19.

The sensitivity of growth hormone secretion to medical treatment in acromegalic patients: influence of age and sex.

van der Lely AJ, Harris AG, Lamberts SW.

Clin Endocrinol (Oxf). 1992 Aug;37(2):181-5.

PMID:
1395069
20.

The sensitivity of growth hormone and prolactin secretion to the somatostatin analogue SMS 201-995 in patients with prolactinomas and acromegaly.

Lamberts SW, Zweens M, Klijn JG, van Vroonhoven CC, Stefanko SZ, Del Pozo E.

Clin Endocrinol (Oxf). 1986 Aug;25(2):201-12.

PMID:
2878748

Supplemental Content

Support Center